Efficacy and safety of obinutuzumab
Report from the American Society of Hematology Annual Meeting
To view the complete article click
here (pdf format)
Commentary: Chemoimmunotherapy involving
rituximab (R) has resulted in PFS and overall survival (OS) advantages in patients with previously untreated advanced-stage follicular lymphoma (FL) and other iNHL. Despite the efficacy of rituximab, relapse occurs in over 30% of patients. Obinutuzumab (O) is a glycoengineered type II anti-CD20 monoclonal antibody that results in higher levels of antibody-dependent cellular cytotoxicity and direct cell death than rituximab.